Brooks Laboratories
Brooks Laboratories (BROOKS) share price was ₹59.90 at the 28 Oct 2026 close; market capitalisation ₹176 Cr; P/E (TTM) 13.34; sector Healthcare. The share price fell 43.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 10.0% year on year to ₹22.96 Cr and net profit was −₹1.79 Cr, against ₹9.58 Cr a year earlier (compared with Jun 2025). Promoters held 52.62% of Brooks Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 53/100 (Average) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 29 Oct 2026, 10:45 IST · EPS basis: Consolidated · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,768.20 | 35.08 | 4,24,250 Cr | 5.08 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,670.00 | 87.77 | 2,56,708 Cr | 15.32 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,609.00 | 72.35 | 1,75,312 Cr | 9.54 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,187.60 | 108.08 | 1,18,199 Cr | 22.30 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,181.00 | 26.28 | 1,17,805 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,339.00 | 34.68 | 1,11,764 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,364.90 | 32.70 | 1,10,265 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Brooks Laboratories (this company) | ₹64.68 | 14.41 | 191 Cr | 1.55 | 0.00% | 20.04% | 20.12% | 96 Cr | 13 Cr |
| Median 8 companies | ₹1,566.55 | 34.88 | 1,18,002 Cr | 4.72 | 0.47% | 14.56% | 18.45% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 100/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has delivered good profit growth of 26.6% CAGR over last 5 years
Weaknesses
5- The company has delivered a poor sales growth of 2.11% over past five years.
- Company has a low return on equity of -2.02% over last 3 years.
- Contingent liabilities of Rs.123 Cr.
- Earnings include an other income of Rs.13.0 Cr.
- Promoter holding has decreased over last 3 years: -11.0%
Technical Indicators
Oscillators
Neutral
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin -5.84% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.7 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 | 16.57 | 20.21 | 22.96 |
| Expenses | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.2 | 22.02 | 24.58 | 22.38 | 20.93 | 15.84 | 19.53 | 24.3 |
| Operating Profit | -3.91 | -1.1 | -3.37 | -9.53 | -1.92 | -3.41 | -1.5 | -1.26 | 3.13 | 2.52 | 0.73 | 0.68 | -1.34 |
| OPM % | -24.9% | -4.52% | -15.49% | -53.78% | -10.71% | -16.4% | -7.31% | -5.4% | 12.27% | 10.75% | 4.41% | 3.36% | -5.84% |
| Other Income | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.2 | 0.03 | 0.62 | 7.15 | 6.13 | 5.32 | 1.35 | 0.18 |
| Interest | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.3 | 0.28 | 0.16 | 0.09 | 0.21 |
| Depreciation | 0.44 | 0.44 | 0.43 | 0.46 | 0.4 | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 | 0.39 | 0.41 | 0.42 |
| PBT | -4.47 | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -2.13 | -1.29 | 9.59 | 7.98 | 5.5 | 1.53 | -1.79 |
| Tax % | 0% | 0% | 0.78% | 0% | 0% | 0% | 0% | 13.95% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -4.47 | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -2.13 | -1.46 | 9.58 | 7.98 | 5.5 | 1.52 | -1.79 |
| EPS (₹) | -1.71 | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -0.81 | -0.5 | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 77 | 91 | 63 | 79 | 83 | 86 | 83 |
| Expenses | 77 | 105 | 93 | 97 | 91 | 79 | 81 |
| Operating Profit | 1 | -14 | -30 | -18 | -8 | 7 | 3 |
| OPM % | 0.7% | -16% | -47% | -22% | -10% | 8% | 3.1% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 20 | 13 |
| Interest | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 | 2 | 2 |
| PBT | -9 | -24 | -38 | -20 | -10 | 25 | 13 |
| Tax % | 115% | -19% | -19% | 0% | 2% | 0% | — |
| Net Profit | -19 | -19 | -31 | -20 | -10 | 25 | 13 |
| EPS (₹) | -7.4 | -4.31 | -7.97 | -7.46 | -3.38 | 8.34 | 4.49 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 93 |
| Borrowings | 31 | 25 | 7 | 6 | 8 | 9 |
| Other Liabilities | 52 | 83 | 29 | 19 | 18 | 17 |
| Total Liabilities | 162 | 196 | 110 | 90 | 124 | 148 |
| Fixed Assets | 108 | 110 | 15 | 14 | 14 | 15 |
| CWIP | 1 | 15 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 92 |
| Other Assets | 54 | 71 | 31 | 34 | 36 | 40 |
| Total Assets | 162 | 196 | 110 | 90 | 124 | 148 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 4 | -37 | -14 | -10 | 3 | 9 |
| Investing | -5 | -25 | 0 | 0 | -45 | -3 |
| Financing | 1 | 64 | 11 | 10 | 42 | 0 |
| Net Cash Flow | 0 | 2 | -3 | 0 | 0 | 7 |
| Free Cash Flow | -1 | -62 | -15 | -10 | 2 | 6 |
| CFO/EBITDA | 1,519 | 261 | 48 | 56 | -26 | 131 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 65 | 71 | 74 | 75 | 88 | 69 |
| Inventory Days | 178 | 157 | 80 | 60 | 61 | 77 |
| Days Payable | 233 | 159 | 165 | 97 | 90 | 80 |
| Cash Conversion Cycle | 9 | 68 | -12 | 38 | 59 | 66 |
| Working Capital Days | -85 | 34 | -37 | 34 | 43 | 34 |
| ROCE % | — | -16% | -30% | -25% | -10% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Brooks Laboratories insights
68 extracted metrics + investor summaries across FY09–FY27.
Documents
Frequently Asked Questions about Brooks Laboratories
What does Brooks Laboratories Ltd do?
Where is Brooks Laboratories Ltd (BROOKS) listed?
Which sector does Brooks Laboratories Ltd belong to?
What is the market capitalisation of Brooks Laboratories Ltd?
What is the PE ratio of Brooks Laboratories Ltd?
What is the 52-week high and low of Brooks Laboratories Ltd?
What is the Return on Equity (ROE) of Brooks Laboratories Ltd?
Company Information
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BROOKS.md for Brooks Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.